Renal Disease Research Takes a Leap Forward with AI-Driven Innovations from Aiosyn and HistoWiz
New York City, USA - October 2023: In a groundbreaking development set to advance the field of renal disease research, Aiosyn, a leading company in AI-enabled tissue analysis, has partnered with digital pathology solutions provider HistoWiz. This collaboration aims to enhance the efficacy and precision of preclinical studies through innovative AI technology.
Patrick de Boer, CEO of Aiosyn, expressed his enthusiasm for the partnership, stating, "We are excited to partner with HistoWiz to harness the potential of AI in renal disease preclinical research. Our NephroPath algorithms transform kidney tissue analysis by delivering quantitative, detailed assessments essential for advancing drug development studies. By integrating with PathologyMap, we can provide HistoWiz’s biopharma and research clients with comprehensive insights that will facilitate the discovery and development of new treatments."
Aiosyn's NephroPath algorithms offer a sophisticated and automated assessment of kidney tissues, identifying and quantifying critical structures such as healthy and atrophic tubules, glomeruli, and the interstitium. This detailed analysis not only improves the efficiency of studies but is also adaptable to meet the specific needs of various research projects.
Highlighting the strategic importance of this technological integration, Linh Hoang, MD, PhD, and CEO of HistoWiz, remarked, "The integration of NephroPath algorithms marks a significant step forward in enhancing our PathologyMap platform, providing our clients with unparalleled precision and efficiency, particularly in the realm of kidney disease research. This collaboration underscores our commitment to advancing healthcare through innovative AI technologies, ensuring that our researchers and biopharma clients receive the most advanced tools for their groundbreaking work."
HistoWiz's PathologyMap is an innovative digital slide management platform that allows users to instantly view, manage, and share their digital slides. With the addition of the state-of-the-art NephroPath algorithms, the platform is set to offer even greater precision and speed in data analysis, further sharpening the focus on kidney disease research.
Both organisations have made it clear that this partnership is geared towards significant advancements in the discovery and development of new renal disease treatments. For those seeking more information about PathologyMap or the integration of NephroPath, HistoWiz’s sales and customer service representatives can be contacted via their website, www.histowiz.com. Additionally, demonstrations of NephroPath’s technology are available through enquiries at Aiosyn, which can be reached at [email protected].
The collaboration between Aiosyn and HistoWiz signifies a pivotal moment in the use of AI to bolster renal disease research, bringing forth a new era of precise and efficient medical discoveries.
Source: Noah Wire Services